Khamseh Mohammad Ebrahim, Mohajeri Tehrani Mohammad Reza, Mousavi Zohreh, Malek Mojtaba, Imani Mehrnaz, Hoshangian Tehrani Nasim, Ghorbani Mohammad, Akbari Hamideh, Sarvghadi Farzaneh, Amouzegar Atieh, Esfahanian Fatemeh, Hashemi Madani Nahid, Emami Zahra
Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences (IUMS), Tehran, Iran.
Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
Arch Iran Med. 2017 Dec 31;20(12):746-751.
This study was designed to present initial results on clinical presentation, therapeutic modalities, and outcome information of patients with pituitary tumors registered in Iran Pituitary Tumor Registry (IPTR).
We collected data from a web-based electronic medical records of patients with various pituitary tumors referred to four tertiary care centers in the country. Retrospective analysis was performed on demographic, clinical, and therapeutic information of 298 patients including 51 clinically nonfunctioning adenoma (CNFA), 85 acromegaly, 135 prolactinoma, and 27 Cushing's disease (CD).
From October 2014 to July 2016, 298 people with the diagnosis of pituitary tumor were registered. Prolactinoma was the most prevalent tumor (45.3%), followed by Acromegaly (28.6%), CNFPA (17.1%), and CD (9%). Female dominance was seen among patients with prolactinoma and CD, while the majority of patients with CNFPA were male and acromegaly was equally distributed between men and women. Hypogonadal symptoms were almost always seen in all types of pituitary groups. Surgery alone was the most common therapeutic modality used in cases of acromegaly, CNFPA, and CD. However, medical therapy alone was frequently applied for cases of prolactinoma. Finally, biochemical cure was achieved in most cases of prolactinoma and CD, but only in 36.5% of acromegalics. Moreover, 80% of patients suffering from CNFPA showed no residual tumor in their imaging.
In conclusion, this comprehensive tumor registry enables early identification, selection of best therapeutic approaches, and evaluation of long-term treatment outcomes. Furthermore, this registry can be used to improve surveillance protocols.
本研究旨在呈现伊朗垂体肿瘤登记处（IPTR）登记的垂体肿瘤患者的临床表现、治疗方式及预后信息的初步结果。
我们从该国四个三级医疗中心收治的各类垂体肿瘤患者的基于网络的电子病历中收集数据。对298例患者的人口统计学、临床和治疗信息进行回顾性分析，其中包括51例临床无功能腺瘤（CNFA）、85例肢端肥大症、135例泌乳素瘤和27例库欣病（CD）。
2014年10月至2016年7月，登记了298例诊断为垂体肿瘤的患者。泌乳素瘤是最常见的肿瘤（45.3%），其次是肢端肥大症（28.6%）、CNFPA（17.1%）和CD（9%）。泌乳素瘤和CD患者中女性占主导，而CNFPA患者大多数为男性，肢端肥大症在男女中分布均衡。性腺功能减退症状几乎在所有类型的垂体肿瘤组中均可见。单独手术是肢端肥大症、CNFPA和CD病例中最常用的治疗方式。然而，泌乳素瘤病例经常单独采用药物治疗。最后，大多数泌乳素瘤和CD病例实现了生化治愈，但肢端肥大症患者中只有36.5%实现了生化治愈。此外，80%的CNFPA患者影像学检查显示无残留肿瘤。
总之，这个综合肿瘤登记处有助于早期识别、选择最佳治疗方法并评估长期治疗结果。此外，该登记处可用于改进监测方案。
